Bimekizumab Demonstrated Sustained Long-Term Improvements in Health-Related Quality of Life and Work Productivity in Patients With Active Psoriatic Arthritis: 3-Year Results from Two Phase 3 Studies
Author(s)
William Tillett, Bachelor of Medicine and Bachelor of Surgery1, Laure Gossec, MD, PhD2, Ennio Lubrano, MD, PhD, MSc3, Maarten de Wit, PhD4, Barbara Ink, PhD5, Patrick Healy, MS6, Jérémy Lambert, MSc, PhD7, Michael Frank Mørup, MSc8, Jessica A. Walsh, MD9.
1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, 3Università del Molise, Campobasso, Italy, 4Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, 5UCB, Slough, United Kingdom, 6UCB, Morrisville, NC, USA, 7UCB, Colombes, France, 8UCB, Copenhagen, Denmark, 9Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, USA.
1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, 3Università del Molise, Campobasso, Italy, 4Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, 5UCB, Slough, United Kingdom, 6UCB, Morrisville, NC, USA, 7UCB, Colombes, France, 8UCB, Copenhagen, Denmark, 9Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, USA.
OBJECTIVES: To demonstrate the long-term impact of bimekizumab treatment on health-related quality of life (HRQoL) and work productivity to 3 years in patients with psoriatic arthritis (PsA).
METHODS: BE OPTIMAL (NCT03895203; biologic disease-modifying antirheumatic drug [bDMARD]-naïve) and BE COMPLETE (NCT03896581; tumour necrosis factor inhibitor inadequate response/intolerance [TNFi-IR]) assessed subcutaneous bimekizumab 160mg every 4 weeks in patients with PsA. Placebo patients switched to bimekizumab (placebo/bimekizumab) at Week16. Study completers could enter BE VITAL (open-label extension; NCT04009499).
HRQoL, physical function and work productivity were assessed using EQ-5D-3L visual analogue scale (VAS), Short Form 36-item Health Survey (SF-36) physical component summary (PCS) and Work Productivity and Activity Impairment (WPAI) Questionnaire, respectively.
Data reported for Bimekizumab Total (placebo/bimekizumab and bimekizumab-randomised patients) to Week148/Week156 (bDMARD-naïve/TNFi-IR) using observed case or multiple imputation.
RESULTS: Week148/156 completion for Bimekizumab Total patients: 555/712 (77.9%) bDMARD-naïve and 299/400 (74.8%) TNFi-IR. Mean baseline scores (SD): EQ-5D-3L VAS 56.5 (20.0; n=711) bDMARD-naïve, 54.4 (20.4; n=400) TNFi-IR; SF-36 PCS 37.6 (9.5; n=711), 36.3 (9.4; n=400); overall work impairment 35.9 (26.8; n=443), 40.5 (27.9; n=231) in employed patients.
Improvements from baseline in EQ-5D-3L VAS (CfB [SD]) sustained from Week52/40 (16.9 [26.9] bDMARD-naïve; 17.2 [27.2] TNFi-IR) to Week148/156 (17.3 [26.6] bDMARD-naïve; 17.2 [30.2] TNFi-IR).
Improvements from baseline in SF-36 PCS (CfB [95% CI]) sustained from Week52/40 (8.3 [7.5, 9.0] bDMARD-naïve; 8.2 [7.2, 9.2] TNFi-IR) to Week148/156 (8.4 [7.7, 9.1] bDMARD-naïve; 8.8 [7.8, 9.9] TNFi-IR).
Improvements from baseline in percent overall work impairment (CfB [95% CI]) sustained from Week52/40 (-18.4 [-21.4, -15.4] bDMARD-naïve; -21.5 [-25.3, -17.8] TNFi-IR) to Week148/156 (-17.3 [-20.6, -13.9] bDMARD-naïve; -21.3 [-26.2, -16.3] TNFi-IR). Similar improvements observed for presenteeism (impairment while working) and activity impairment.
CONCLUSIONS: Bimekizumab-treated patients with PsA demonstrated sustained improvements to 3 years in HRQoL, physical function and work productivity; improvements were consistent across bDMARD-naïve and TNFi-IR patients.
METHODS: BE OPTIMAL (NCT03895203; biologic disease-modifying antirheumatic drug [bDMARD]-naïve) and BE COMPLETE (NCT03896581; tumour necrosis factor inhibitor inadequate response/intolerance [TNFi-IR]) assessed subcutaneous bimekizumab 160mg every 4 weeks in patients with PsA. Placebo patients switched to bimekizumab (placebo/bimekizumab) at Week16. Study completers could enter BE VITAL (open-label extension; NCT04009499).
HRQoL, physical function and work productivity were assessed using EQ-5D-3L visual analogue scale (VAS), Short Form 36-item Health Survey (SF-36) physical component summary (PCS) and Work Productivity and Activity Impairment (WPAI) Questionnaire, respectively.
Data reported for Bimekizumab Total (placebo/bimekizumab and bimekizumab-randomised patients) to Week148/Week156 (bDMARD-naïve/TNFi-IR) using observed case or multiple imputation.
RESULTS: Week148/156 completion for Bimekizumab Total patients: 555/712 (77.9%) bDMARD-naïve and 299/400 (74.8%) TNFi-IR. Mean baseline scores (SD): EQ-5D-3L VAS 56.5 (20.0; n=711) bDMARD-naïve, 54.4 (20.4; n=400) TNFi-IR; SF-36 PCS 37.6 (9.5; n=711), 36.3 (9.4; n=400); overall work impairment 35.9 (26.8; n=443), 40.5 (27.9; n=231) in employed patients.
Improvements from baseline in EQ-5D-3L VAS (CfB [SD]) sustained from Week52/40 (16.9 [26.9] bDMARD-naïve; 17.2 [27.2] TNFi-IR) to Week148/156 (17.3 [26.6] bDMARD-naïve; 17.2 [30.2] TNFi-IR).
Improvements from baseline in SF-36 PCS (CfB [95% CI]) sustained from Week52/40 (8.3 [7.5, 9.0] bDMARD-naïve; 8.2 [7.2, 9.2] TNFi-IR) to Week148/156 (8.4 [7.7, 9.1] bDMARD-naïve; 8.8 [7.8, 9.9] TNFi-IR).
Improvements from baseline in percent overall work impairment (CfB [95% CI]) sustained from Week52/40 (-18.4 [-21.4, -15.4] bDMARD-naïve; -21.5 [-25.3, -17.8] TNFi-IR) to Week148/156 (-17.3 [-20.6, -13.9] bDMARD-naïve; -21.3 [-26.2, -16.3] TNFi-IR). Similar improvements observed for presenteeism (impairment while working) and activity impairment.
CONCLUSIONS: Bimekizumab-treated patients with PsA demonstrated sustained improvements to 3 years in HRQoL, physical function and work productivity; improvements were consistent across bDMARD-naïve and TNFi-IR patients.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR31
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Biologics & Biosimilars, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), No Additional Disease & Conditions/Specialized Treatment Areas